Public Profile

Covis Pharma B.V.

Covis Pharma B.V., headquartered in the Netherlands, is a prominent player in the pharmaceutical industry, specialising in the development and commercialisation of innovative therapies for patients with respiratory and cardiovascular conditions. Founded in 2015, Covis Pharma has rapidly established itself as a trusted provider of essential medications, focusing on areas such as asthma, chronic obstructive pulmonary disease (COPD), and hypertension. With a commitment to improving patient outcomes, Covis Pharma offers a range of unique products that address unmet medical needs. The company’s strategic approach to drug development and its robust portfolio have positioned it as a key competitor in the global market. Notable achievements include successful partnerships and a growing presence in major operational regions across Europe and North America, reinforcing its dedication to enhancing healthcare solutions worldwide.

DitchCarbon Score

How does Covis Pharma B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

3

Industry Benchmark

Covis Pharma B.V.'s score of 18 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.

23%

Let us know if this data was useful to you

Covis Pharma B.V.'s reported carbon emissions

Covis Pharma B.V., headquartered in the Netherlands, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the company is likely aware of the growing importance of climate commitments within the pharmaceutical industry. As such, it may be engaging in initiatives aimed at reducing its environmental impact, although specific details on these initiatives or any climate pledges have not been disclosed.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Covis Pharma B.V.'s primary industry is Real estate services (70), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Covis Pharma B.V. is in NL, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Covis Pharma B.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Chiesi Farmaceutici

IT
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Chiesi Ltd.

GB
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Boehringer Ingelheim Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Regeneron

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Merck Sharp & Dohme LLC

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Novartis

CH
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers